Investors with a lot of money to spend have taken a bearish stance on Viking Therapeutics VKTX.
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VKTX, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 11 options trades for Viking Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 45% bullish and 54%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $58,200, and 10, calls, for a total amount of $402,660.
What's The Price Target?
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $12.0 and $90.0 for Viking Therapeutics, spanning the last three months.
Volume & Open Interest Trends
In terms of liquidity and interest, the mean open interest for Viking Therapeutics options trades today is 348.2 with a total volume of 608.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Viking Therapeutics's big money trades within a strike price range of $12.0 to $90.0 over the last 30 days.
Viking Therapeutics 30-Day Option Volume & Interest Snapshot
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| VKTX | CALL | SWEEP | BULLISH | 04/19/24 | $90.00 | $88.5K | 794 | 204 |
| VKTX | PUT | TRADE | BEARISH | 04/19/24 | $65.00 | $58.2K | 527 | 72 |
| VKTX | CALL | SWEEP | BEARISH | 08/16/24 | $70.00 | $45.5K | 103 | 25 |
| VKTX | CALL | TRADE | NEUTRAL | 01/16/26 | $20.00 | $41.5K | 204 | 8 |
| VKTX | CALL | TRADE | BULLISH | 04/19/24 | $80.00 | $41.5K | 689 | 127 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Current Position of Viking Therapeutics
- Currently trading with a volume of 1,142,080, the VKTX's price is down by -2.03%, now at $70.5.
- RSI readings suggest the stock is currently may be overbought.
- Anticipated earnings release is in 41 days.
Professional Analyst Ratings for Viking Therapeutics
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $90.2.
- An analyst from HC Wainwright & Co. downgraded its action to Buy with a price target of $90.
- An analyst from Truist Securities persists with their Buy rating on Viking Therapeutics, maintaining a target price of $120.
- Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Viking Therapeutics, targeting a price of $116.
- An analyst from Stifel persists with their Buy rating on Viking Therapeutics, maintaining a target price of $35.
- An analyst from HC Wainwright & Co. has decided to maintain their Buy rating on Viking Therapeutics, which currently sits at a price target of $90.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Viking Therapeutics, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
